Dermata Therapeutics, Inc. (DRMA): Price and Financial Metrics


Dermata Therapeutics, Inc. (DRMA): $0.33

0.04 (+15.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DRMA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

DRMA Stock Price Chart Interactive Chart >

Price chart for DRMA

DRMA Price/Volume Stats

Current price $0.33 52-week high $2.45
Prev. close $0.29 52-week low $0.16
Day low $0.29 Volume 898,000
Day high $0.35 Avg. volume 744,250
50-day MA $0.36 Dividend yield N/A
200-day MA $0.62 Market Cap 4.07M

Dermata Therapeutics, Inc. (DRMA) Company Bio


Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. Its lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. The company was founded in 2014 and is headquartered in San Diego, California.


DRMA Latest News Stream


Event/Time News Detail
Loading, please wait...

DRMA Latest Social Stream


Loading social stream, please wait...

View Full DRMA Social Stream

Latest DRMA News From Around the Web

Below are the latest news stories about DERMATA THERAPEUTICS INC that investors may wish to consider to help them evaluate DRMA as an investment opportunity.

Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea

/ Dermata Therapeutics, Inc. ("Dermata" or the "Company") (Nasdaq:DRMA)(DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced topline results from its Phase 2 trial of once-weekly topical application of DMT310 for the treatment of moderate-to-severe rosacea.

Yahoo | December 5, 2022

Maxim Group Reaffirms Their Buy Rating on Dermata Therapeutics (DRMA)

Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Dermata Therapeutics (DRMA - Research Report) yesterday and set a price target of $4.00. The company's shares closed yesterday at $0.74.According to TipRanks, Vendetti is an analyst with an average return of -4.6% and a 32.40% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Pulse Biosciences, ReShape Lifesciences, and Venus Concept.Dermata Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $4.93 and a one-year low of $0.44. Currently, Dermata Therapeutics has an average volume of 272.8K.

Austin Angelo on TipRanks | November 17, 2022

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Dermata Therapeutics, Inc. (Nasdaq:DRMA;DRMAW) ("Dermata," or the "Company"), a clinical-stage biopharmaceutical company focusing on the treatment of medical and aesthetic skin conditions, today highlighted recent corporate progress, and reported financial results for the quarter ended September 30, 2022.

Yahoo | November 10, 2022

Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that Gerry Proehl, Dermata's Chairman of the Board, President, and Chief Executive Officer will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022.

Yahoo | September 6, 2022

Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase

/ Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata," or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that Dermata will participate in the Gilmartin Group Emerging Growth Company Showcase, being held on August 31, 2022.

Yahoo | August 24, 2022

Read More 'DRMA' Stories Here

DRMA Price Returns

1-mo 71.79%
3-mo -52.35%
6-mo -43.22%
1-year -83.25%
3-year N/A
5-year N/A
YTD -19.32%
2022 -76.49%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7574 seconds.